Nalaganje...
Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations
Azacitidine is recommended for patients with higher-risk myelodysplastic syndromes (MDS) who are not eligible for intensive therapy or for patients with lower-risk MDS who have thrombocytopenia or neutropenia or have anemia that is unresponsive to other therapies. However, standard treatment with az...
Shranjeno v:
| Main Authors: | , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
2013
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3698413/ https://ncbi.nlm.nih.gov/pubmed/23826577 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5045/br.2013.48.2.87 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|